Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | ENTPD5 | O75356 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600523 | 0.93 | AKT1 (0.46) | AKT1ESR1ESR2NR3C1PGR | |
| SCHEMBL5846302 | 0.80 | AKT1 (0.60) | AKT1ESR1ESR2NR3C1PGR | |
| SCHEMBL547117 | 0.72 | SIGMAR1 (0.42) | — | |
| SCHEMBL7787622 | 0.71 | AKT1 (0.51) | AKT1ESR1ESR2PTGS2PTPN1 | |
| SCHEMBL10824418 | 0.69 | ESR2 (0.38) | AKT1ESR1ESR2NR3C1PGR | |
| SCHEMBL27526924 | 0.69 | AKT1 (0.41) | AKT1ESR1ESR2PTGS1PTGS2 | |
| SCHEMBL3184205 | 0.68 | AKT1 (0.56) | AKT1ESR1ESR2ENTPD5CETP | |
| SCHEMBL30513267 | 0.68 | AKT1 (0.56) | AKT1ESR1ESR2ENTPD5CETP | |
| SCHEMBL4475359 | 0.68 | AKT1 (0.49) | AKT1ESR1ESR2PTPN1ENTPD5 | |
| SCHEMBL6130742 | 0.67 | AKT1 (0.42) | AKT1ESR1ESR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8840883-B2 | Metallo-protein and tocotrienol (MP-T3) compositions with non-protein-type metal chelator and uses thereof | NAIDU LP (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130071372-A1 | METALLO-PROTEIN AND TOCOTRIENOL (MP-T3) COMPOSITIONS WITH NON-PROTEIN-TYPE METAL CHELATOR AND USES THEREOF | NAIDU LP (US) | 2013-03-21 | — | — | US | disclosed |
| US-8309080-B2 | Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof | NAIDU LP (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090148433-A1 | METALLO-PROTEIN AND TOCOTRIENOL (MP-T3) COMPOSITIONS AND USES THEREOF | NAIDU LP (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2005035490-A3 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS | YASOO HEALTH INC (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | COULADOUROS ELIAS A (GR) | 2005-06-09 | — | — | US | disclosed |
| WO-2005035490-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | UGT8, DDOST, GGPS1 | AKT1 3679/4885ESR1 3170/4885ESR2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.